MiMedx Group, Inc. provided sales guidance for the year 2022. The company maintained its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | +0.28% |
|
+5.01% | -18.70% |
Jul. 02 | Cantor Fitzgerald Initiates MiMedx at Overweight Rating With $11 Price Target | MT |
Jul. 01 | MiMedx Group, Inc.(NasdaqCM:MDXG) added to Russell 3000 Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.70% | 1.05B | |
-13.16% | 139M | |
-21.75% | 58.42M | |
+1.08% | 57.41M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx Group, Inc. Provides Sales Guidance for the Year 2022